Details of FDA approval of mitapivat-Pyrukynd

Mitapivat (mitapivat), trade namePyrukynd, is the first disease-modifying therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. This approval marks a new stage in the treatment of PK deficiency, providing patients with the first targeted and long-term oral treatment option. PK deficiency is a rare, lifelong hemolytic anemia. Patients may face significant anemia symptoms, fatigue, jaundice and related complications throughout their lives, seriously affecting their quality of life. MetapivalAs the first oral PK activator, it brings real disease-modifying potential to patients by improving red blood cell energy metabolism and delaying the hemolysis process.

The FDA's approval of Metapival was based on two key clinical trials - ACTIVATE and ACTIVATE-T. These two studies focused on adults with PK deficiency who were not regularly transfused and those who were regularly transfused. In the ACTIVATE trial, mitapivasignificantly improved hemoglobin levels. The results showed that 40% of patients treated with mitava achieved the preset hemoglobin response, while no patients in the placebo group achieved the target (two-sided p<0.0001). In addition, secondary endpoints also showed significant improvements, including hemolysis markers and indicators of ineffective erythropoiesis. Daily records of patients' symptoms showed that treatment with Metapival effectively reduced jaundice, fatigue and shortness of breath, with low scores indicating a reduction in the severity of signs or symptoms, and an overall improvement in the patient's life experience.

The ACTIVATE-T trial targeted patients with PK deficiency who underwent regular blood transfusions and showed that mitapiva can significantly reduce the burden of blood transfusions. Trial results showed that 33% of patients achieved a ≥33% reduction in blood transfusion volume during the fixed-dose period, and 22% of patients did not require blood transfusions during the fixed-dose period. This result is clinically important and offers potential improvements in quality of life and risk reduction in complications for patients who are chronically dependent on blood transfusions. Adverse reactions in ACTIVATE-T were generally consistent with the ACTIVATE trial, showing that the drug was generally well tolerated.

Regarding safety, common adverse reactions of Metapival include abnormal laboratory indicators, such as decreased male estrone, increased uric acid, back pain, decreased male estradiol, and joint pain. The incidence of serious adverse events was low, with only a few patients experiencing atrial fibrillation, gastroenteritis, fractures, or musculoskeletal pain, each event occurring in a single case. Overall, metapival has good safety and tolerability, and is suitable for long-term use in adult patients with PK deficiency who require disease-modifying treatment.

The approval of metapival not only provides a new treatment option for patients with PK deficiency, but also represents a milestone in the targeted treatment of rare blood diseases. This oral PK activator provides patients with disease improvement beyond symptom control by directly improving red blood cell metabolic function, significantly alleviating hemolysis and increasing hemoglobin levels. With the accumulation of clinical experience and the release of long-term follow-up data, Metapival is expected to further optimize the treatment strategy for adult PK deficiency in the future, bringing sustained and stable efficacy and better quality of life to patients with rare hemolytic anemia.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd